Literature DB >> 31755977

Complete Posterior Vitreous Detachment Reduces the Need for Treatment of Diabetic Macular Edema.

William Anderson, Kisha Piggott, Yicheng K Bao, Hang Pham, Sweta Kavali, Rithwick Rajagopal.   

Abstract

BACKGROUND AND
OBJECTIVE: To evaluate the vitreomacular interface and its relation to treatment burden for diabetic macular edema (DME) in patients without overt vitreomacular traction (VMT). PATIENTS AND METHODS: A retrospective cohort study of 494 eyes from 274 patients who had macular spectral-domain optical coherence tomography (SD-OCT) and did not have proliferative diabetic retinopathy, DME, or VMT at the initial visit. Posterior vitreous detachment (PVD) was categorized at the initial visit into five stages (0-4) using SD-OCT parameters alone.
RESULTS: Two of 34 eyes (6.9%) presenting with a complete PVD required DME treatment during follow-up, whereas 144 of 460 eyes (31.3%) without a complete PVD at baseline required treatment (P = .001, Chi-squared). After adjusting for age, ethnicity, gender, and HbA1c, complete PVD at baseline was associated with a significant reduction in risk of DME therapy (hazard ratio: 0.18; 95% confidence interval, 0.05-0.73; P = .02).
CONCLUSION: Complete PVD is independently associated with a reduced need for DME treatment. [Ophthalmic Surg Lasers Imaging Retina. 2019;50:e266-e273.]. Copyright 2019, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31755977     DOI: 10.3928/23258160-20191031-13

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging Retina        ISSN: 2325-8160            Impact factor:   1.300


  2 in total

1.  Factors associated with diabetic macular edema in patients with proliferative diabetic retinopathy.

Authors:  John R O'Fee; Joseph Juliano; Andrew A Moshfeghi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-02-22       Impact factor: 3.117

2.  Vitreous microparticles contain apoptotic signals suggesting a diabetic vitreopathy.

Authors:  Harris Sultan; Rithwick Rajagopal; Prabakar Kumar Rao; Kisha Deslee Piggott; Michael A Paley; Lynn Marisa Hassman; Albert S Li; Brigid Marshall; Rajendra Shridhar Apte
Journal:  Int J Ophthalmol       Date:  2022-01-18       Impact factor: 1.645

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.